En route pour la phase expérimentale du cannabis à usage médical https://ansm.sante.fr/Dossiers/Cannabis-a-usage-medical/En-route-pour-la-phase-experimentale-du-cannabis-a-usage-medical/(offset)/2#paragraph_169669 Afin de poursuivre les travaux nécessaires à la mise en place de cette expérimentation, l’ANSM a créé un comité scientifique pluridisciplinaire , composé notamment de professionnels de santé et de patients. Sa mission est de produire les cahiers des charges suivants : les médicaments utilisés durant l’expérimentation, les formations (contenu des modules prescripteurs, dispensateurs et une information des patients), le contenu du registre de suivi des patients. Le 25 octobre 2019 , L'Assemblée nationale donne son feu vert à une expérimentation de l'usage médical du cannabis dans le cadre de l'examen [...]
Lire la suiteCannabis non récréatif : cherche volontaires pour formation accélérée (3h30 en e-leaning) Jean-Yves NAU, 30 janvier 2020 https://jeanyvesnau.com/2020/01/30/cannabis-non-recreatif-cherche-volontaires-pour-formation-acceleree-3h30-en-e-leaning/ addictions, Douleur, Médecine, médicament, Polémique, Risques (réduction des) Bonjour Très très lentement mais sûrement : le cannabis thérapeutique verra le jour en France. En témoignent les travaux des experts d’un Comité scientifique temporaire (CST). Un comité intitulé « mise en œuvre de l’expérimentation du cannabis médical en France ». Ils oeuvrent sous l’égide de l’Agence nationale de sécurité du médicament et des produits de santé (ANSM). Et ils viennent « de déterminer les conditions nécessaires à la mise en pratique de cette expérimentation ». Il s’agit [...]
Lire la suiteA dangerous method ? Psychedelic therapy at Modum Bad, Norway, 1961–76 Petter Grahl Johnstad History of Psychiatry, 2020, 1–10 Doi : 10.1177/0957154X19894537 Abstract After many years of disregard, the use of psychedelic drugs in psychiatric treatment has re-emerged in recent years. The prospect that psychedelics may again be integrated into mainstream psychiatry has aroused interest in long-forgotten research and experience from the previous phase of psychedelic therapy, which lasted from the late 1940s to the 1970s. This article will discuss one large-scale psychedelic therapy programme at Modum Bad Nervesanatorium, a psychiatric clinic which treated 379 inpatients with psychedelic drugs during the years 1961–76. The psychiatrists [...]
Lire la suite“Go Ask Alice”: The Case for Researching Schedule I Drugs Kenneth V. ISERSON Cambridge Quarterly of Healthcare Ethics, 2019, 28, 168–177. © Cambridge University Press 2018. doi : 10.1017/S0963180118000518 Abstract : The available treatments for disorders affecting large segments of the population are often costly, complex, and only marginally effective, and many have numerous side effects. These disorders include dementias, debilitating neurological disorders, the multiple types of drug addiction, and the spectrum of mental health disorders. Preliminary studies have shown that a variety of psychedelic and similar U.S. Drug Enforcement Administration Schedule I drugs may offer better treatment options than those that currently exist and pose potentially [...]
Lire la suiteTherapeutic Bases of Psychedelic Medicines : Psycho-integrative Effects Michael J. WINKELMAN chapter 1, in "PSYCHEDELIC MEDICINE: SOCIAL, CLINICAL, AND LEGAL PERSPECTIVES" january 2007, pp 1-19. INTRODUCTION For thousands of years, human beings have used medicinal plants to enhance their health and well-being. In cultures around the world, plants commonly referred to as psychedelic, hallucinogens, and entheogens have played central roles in their healing practices. These vision-inducing plants have also played important roles in the religious and spiritual practices of many societies, evoking powerful emotional, cognitive, and therapeutic reactions. These plants that were central to concepts of health, spirituality, and well-being were, however, demonized and rejected [...]
Lire la suiteBibliographie Cannabinoïdes et Opiacés Dr Christian Sueur, GRECC, janvier 2020.
Lire la suiteBeta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106 Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]
Lire la suite'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]
Lire la suiteAre Your Patients Taking CBD? - Medscape - January 15, 2020 https://www.medscape.com/viewarticle/923801 Cannabidiol (CBD) is having its moment in the sun. A Gallup poll from last August found that 1 in 7 Americans use CBD, that 11% of users are 50 to 64 years of age, and that 8% are at least 65 years of age. Pain relief, anxiety, insomnia, and arthritis are the top reasons for use. Nearly 4 in 10 Americans think CBD oils should be legally available for adults to buy over the counter. Although the 2018 Farm Bill removed hemp (cannabis and cannabis derivatives such as CBD that contain less than 0.3% THC) [...]
Lire la suiteCannabinoid Regulation of Fear and Anxiety : an Update Eleni P. Papagianni & Carl W. Stevenson Current Psychiatry Reports, 2019, 21, 38 doi : 10.1007/s11920-019-1026-z Abstract Purpose of Review : Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings : Evidence from preclinical studies has shown that the non-psychotropic phyto-cannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear [...]
Lire la suite